KDM6A Deficiency Induces Myeloid Bias and Promotes CMML‐Like Disease Through JAK/STAT3 Activation by Repressing SOCS3
Advanced Science · 2025
DOI: 10.1002/advs.202413091 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Science, 2025. Verfasst von Huiqiao Chen und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology and Cell Therapy, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang Province, 310016, P.…. Hauptthemen laut MEDLINE: Histone Demethylases, STAT3 Transcription Factor, Suppressor of Cytokine Signaling 3 Protein, Leukemia, Myelomonocytic, Chronic. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 61 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Zhejiang province.
Abstract (Originalsprache)
Chronic myelomonocytic leukemia (CMML) is a hematologic malignancy with a poor prognosis and limited targeted therapies. Lysine demethylase 6A (KDM6A), a H3K27 demethylase and key component of the COMPASS complex, is frequently mutated in hematologic malignancies, but its roles in embryonic hematopoiesis and tumor suppression in CMML remain unclear. Using zebrafish models with kdm6a mutants and integrative multi‐omics analysis (ATAC‐seq, RNA‐seq, ChIP), we find that Kdm6a is a critical positive regulator of hematopoietic stem and progenitor cell (HSPC) emergence via Syk‐related inflammatory signaling in a H3K27me3‐dependent manner. We further find that Kdm6a haploinsufficiency in zebrafish leads to myeloid‐biased hematopoiesis and a CMML‐like disease, similar to CMML patients with reduced KDM6A expression. This KDM6A haploinsufficiency also significantly alters the chromatin landscape of genes associated with aging and cellular homeostasis in HSPCs. Mechanistically, KAM6A haploinsufficiency represses SOCS3 expression, thereby activating JAK/STAT3 signaling in HSPCs. Importantly, inhibitors targeting JAK or STAT3 phosphorylation alleviate myeloid expansion, providing a rationale for JAK/STAT pathway inhibition in CMML therapy. These findings enhance our understanding of CMML pathogenesis and propose new therapeutic avenues.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hematology and Cell Therapy, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang Province, 310016, P. R. China.
- Bone Marrow Transplantation Center, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang Province, 310009, P. R. China.
- Institute of Hematology, Zhejiang University, Hangzhou, Zhejiang Province, 310058, P. R. China.
ORCID-Profile: Huiqiao Chen, Haowen Xiao
Förderung
- National Natural Science Foundation of China
- Natural Science Foundation of Zhejiang province
Zitieren
APA
Chen, H., Wang, S., Dong, R., Yu, P., Li, T., Hu, L., Wang, M., Qian, Z., Zhou, H., Yue, X., Wang, L., & Xiao, H. (2025). KDM6A Deficiency Induces Myeloid Bias and Promotes CMML‐Like Disease Through JAK/STAT3 Activation by Repressing SOCS3. Advanced Science. https://doi.org/10.1002/advs.202413091
Vancouver
Chen H, Wang S, Dong R, Yu P, Li T, Hu L, et al. KDM6A Deficiency Induces Myeloid Bias and Promotes CMML‐Like Disease Through JAK/STAT3 Activation by Repressing SOCS3. Advanced Science. 2025. doi:10.1002/advs.202413091
BibTeX
@article{Chen2025,
author = {Chen, Huiqiao and Wang, Shufen and Dong, Ruoyu and Yu, Pinhui and Li, Tianyu and Hu, Liangning and Wang, Mowang and Qian, Zijun and Zhou, Hongyu and Yue, Xiaoyan and Wang, Limengmeng and Xiao, Haowen},
title = {KDM6A Deficiency Induces Myeloid Bias and Promotes CMML‐Like Disease Through JAK/STAT3 Activation by Repressing SOCS3},
journal = {Advanced Science},
year = {2025},
doi = {10.1002/advs.202413091}
}
EUVIMED